Slide 1: Reimagining Medical Imaging CT
For personal use only REIMAGINING MEDICAL IMAGING CT Enabled by proprietary carbon nanotube X-ray technology Kingsley Hall Chief Executive Officer 25 June 2026
Slide 2: Important Notice
I MP OR T AN T N O TI C E For personal use only THIS PR ES ENTATION HAS B EEN AP PR OVED BY THE B OARD OF M ICR O-X LIM ITED S C O P E & L I M I T A T I O N S This Pres entation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX.M X1). The Pres entation is a s umm ary only which is c
Slide 3: Important Notice - Continued
I MP OR T AN T N O TI C E - C ON T IN U E D For personal use only N O T I N V E S T M E N T A D V I C E The information c ontained in this Presentation is not financial produc t, investm ent, legal, taxation or other advice or any rec omm endation to ac quire securities in the Company. No relianc e
Slide 4: Investment Highlights
INVESTMENT HIG HLIGHTS World leading CT medtech company taking CT imaging to the patient For personal use only • Micro-X develops CT Imaging Systems to bring gold-standard imaging beyond conventional CT's constraints to where the patient needs it – ERs, critical care, trauma, ORs, ambulances, rural,
Slide 5: Imaging's Next Disruption Cycle
IMAGING’S NEXT DISRUPTION CY CLE Medical imaging is not evolving – it is resetting. NEX is the new architecture For personal use only CURRENT ARCHITECTURE IS UNDER STRAIN NEX: A NEW ARCHITECTURE, NOT AN UPGRADE ▪ Diminishing returns: more slices, faster processing and better ▪ Fundamentally differen
Slide 6: CT Commercial Pathway
CT COMMERCIAL PATHWAY Bringing a Portfolio of Medical CT Products to Market For personal use only PRODUCTS FUND ING / STATUS MA RKET ( TAM ) CY2026 CY2 027 CY2 028 Mobile Head CT Regulatory Test bench completed Hospital and Ambulance Submission Human Imaging Trials $8M ASA funding to prototype deliv
Slide 7: CT Catalysts: 12-24 Months
CT CATA LY STS: 12-24 For personal use only MONTHS DEVELOP MENT HEAD CT FULL BO DY CT Undertaking hospital imaging trials Developing Full Body test bench ▪ Complete hospital human imaging trials at Royal Melbourne and ▪ Complete $12.5M initial ARPA-H funding (up to $25M over 5 years) Royal Adelaide
Slide 8: Commercial & Security: 12-24 Months
COMMERCIAL & SECURITY: 12-24 For personal use only MONTHS CO MMER CIAL PARTNERSHIPS MO BILE DR SECURITY Sales growth - current & new markets Execute security partnerships to unlock value ▪ Launch 2026 model update – lower cost, improved margins ▪ Deliver two additional DHS Checkpoint modules ▪ Roll
Slide 9: Core Technology: X-ray Technology Shift
CORE TECHNOLOGY X-ray Technology Shift For personal use only CONVENTIONAL X-Ray NEX by Micro-X BULKY · INEFFICIENT COMPACT · EFFICIENT Hot filament tube Cold Cathode CNT tube Heated wire sheds electrons, like an incandescent bulb Electric field releases electrons without heat, like an LED. Micro-X h
Slide 10: Validation & Partners
VALIDATION & PARTNERS Non-dilutive funding de-risks our technology development and unlocks value For personal use only DEVELOPMENT Up to $31.7M funding Up to $25M funding $8M funding $4.4M funding PA RT NE RS Checkpoints & Baggage Full Body CT Head CT Head CT Scanner – U.S. Airports – Portable & Lig
Slide 11: The CT Opportunity
For personal use only T HE CT OP POR TU N IT Y Head CT & Full Body CT, our largest addressable markets
Slide 12: The Stroke Problem
THE STROKE PROBLEM Stroke is the leading cause of disability globally, the gap between ambulance and hospital costs lives For personal use only 1 in 4 people will have a New Stroke every 12.2M new US$451B estimated 63% of strokes occur stroke in their lifetime1 3 seconds1 strokes a year1 cost of str
Slide 13: Mobile Stroke Units: Proven, Not Scalable
MOBILE STROKE UNITS: PROVEN, NOT SCALABLE Micro-X Head CT to deliver the same outcomes at a fraction of the cost For personal use only The problem Micro-X advances pre-hospital care Proven: 32.9% of patients treated within 60 min vs 2.6% on standard 10x lighter: the CT shrinks from ~700kg to ~70kg E
Slide 14: Mobile Stroke Unit: Addressable Market
MOBILE STROKE UNIT: ADDRESSABLE MARKET Our Vision: Mobile Stroke Unit for Every Ambulance For personal use only A CT in every ambulance with economics that pay for themselves Illustrative Deployment model: 1 EMT ambulance per 50,000 people in the US and EU; ~240 strokes a year per 100,000 people (US
Slide 15: Head CT: Beyond the Mobile Stroke Unit
HEAD CT: BEYOND THE MOBILE STROKE UNIT Bringing Head CT into Emergency Rooms, Intensive Care, & Operating Rooms For personal use only Head CT need Emergency: head trauma, stroke, severe headache, loss of consciousness, seizures Intensive care: monitoring stroke, infection, brain trauma and hydroceph
Slide 16: Rover: Trailblazing Product
ROVER: TRAILBLAZING PRODUCT Demonstrating core technology and benefits in multiple key markets For personal use only FDA, TGA, CE MDR Trailblazing First CNT cold-cathode X-ray system globally certified by FDA, TGA and CE MDR for human imaging ➢ Same core CNT and high-voltage technology as Head CT an
Slide 17: Security Screening
SECURITY SCREENING Applying Micro-X core technology to rethink airport passenger screening For personal use only Self-Screening Passenger Checkpoint and Miniaturised CT NEX technology enables a new baggage CT: ¼ the size, ¼ the weight, ½ the cost of conventional airport CT Transforms the long conven
Slide 18: Regulatory & Reimbursement Pathway
REGUL ATORY & REIMBURSEMENT PATHWA Y Head CT: pathway from clinical trials to commercial launch across Australia and the United States For personal use only 01 Clinical Validation 02 Regulatory Pathway ✓ Done 2 x Imaging te st benches delivered to ASA ✓ Done FDA 510(k) approval pathway identified wi
Slide 19: Full-Body CT Next-Generation Mobile Imaging
FULL-BODY CT NEXT-GENERATION MOBILE IMA GING ARPA-H funding supports Micro-X’s expansion into full-body CT imaging For personal use only ARPA-H funding to advance full-body CT Initial funding of $12.5M for first 2 years, up to $25M for a total of 5 years Contract to design and deliver a lightweight,
Slide 20: Experienced Leadership
EXPERIENCED LEADERS HIP Execution credentials across CT, medtech, defence programs, manufacturing and commercial scale-up For personal use only Kingsley Hall, CEO Brian Gonzales, PhD, CEO Americas Patrick O'Brien, Non-Exec Chair Jim McDowell, Non-Exec 25+ years’ experience in Industry leader in X-ra
Slide 21: Financial Snapshot
For personal use only FINANCIAL Institutional / Strategic, 40.0% SNAPSHOT Retail and HNW, 57.5% Board & Management, 2.5% FINANCIALS & SHAREHOLDERS SHARE CAPITAL (22 June 2026) $22.2m Contracted Payments FY26 onwards Cash $3.5m (31 March 2026) Share price $0.037 per share $13.1m (FY2025) Revenue Tota
Slide 22: For more information
For personal use only For more information visit: www.micro-x.com Micro-X Limited Investor Enquiries Kingsley Hall, Chief Executive Officer Peter Dickman, Chief Financial Officer Rebecca Puddy, Head of Corporate Tel: +61 8 7099 3966 Communications Email: pdickman@micro-x.com Tel: +61 8 7099 3966 Ema
Slide 23: Glossary of Terms
GLOSSARY OF TERMS For personal use only ARPA-H Advanced Research Projects Agency for Health (USA) GPO Group purchasing organisation ASA Australian Stroke Alliance ICU Intensive care unit CDC Center for Disease Control and Prevention (USA) IGP Industry Growth Program (Australian Government) CE (MDR)